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Thirty-one patients with acute schistosomiasis were evaluated clinically and immunolog-
ically. Cytokine levels were determined in peripheral blood mononuclear cell (PBMC) super-
natants. Levels of total and antigen-specific IgE, tumor necrosis factor (TNF)–a, and immune
complexes were measured in serum samples. Clinical findings included general symptoms,
liver damage, pulmonary involvement, and pericarditis. All patients had eosinophilia. Immune
complexes were detected in 55% of the patients (mean ^ SD, 7.8 ^ 7.6 mg Eq/mL) and were
associated with cough, dyspnea, and abnormal chest radiographic findings. Levels (mean ^
SD) of TNF-a (1349.3 ^ 767.6 pg/mL), interleukin (IL)–1 (2683 ^ 1270 pg/mL), and IL-6 (382 ^
52.3 pg/mL) were elevated in PBMC. Serum TNF-a levels were elevated in 87% of the patients and
were associated with abdominal pain. Higher interferon-g levels were detected in PBMC of patients
with acute disease than in those of patients with chronic schistosomiasis; IL-5 levels were higher in
those with chronic disease. Low IL-5 levels were associated with weight loss. Proinflammatory cyto-
kines and immune complexes with low Th2 responses might explain the immunopathogenesis of
acute schistosomiasis.
Schistosoma mansoni produces 4 clinical conditions: acute
disease and 3 chronic forms (intestinal, hepatointestinal, and
hepatosplenic) [1, 2]. Although the chronic disease is the main
cause of morbidity in endemic regions, the acute disease is
more severe, and death has occurred in China in patients with
acute S. japonicum infection [3–7]. Acute schistosomiasis due
to S. mansoni infection is less severe and has been described as
a toxemic syndrome that occurs 6–8 weeks after initial infec-
tion, manifested by unspecific symptoms, respiratory distress,
and eosinophilia [8–13].
The pathogenesis of acute schistosomiasis has not been estab-
lished. The co-occurrence of eosinophilia and respiratory
distress suggests the presence of an immediate hypersensitivity
reaction [3, 12, 13]. Lawley et al. [14] detected immune com-
plexes in 14 (93%) of 15 persons with acute S. mansoni infection,
but no associations with clinical symptoms were detected. Hiatt
et al. [15] found a correlation between severity of illness and
intensity of infection and a correlation between immune com-
plex levels and disease severity and intensity of infection [16].
The immune responses to pathogens have been defined better
since the Th1-Th2 model of CD4 T helper cell differentiation
has been understood. Th1 cells secrete interferon (IFN)–g and
interleukin (IL)–2 and promote cell-mediated immunity,
whereas Th2 cells secrete IL-4, -5, -10, and -13 and provide B
cells with help for antibody production [17, 18]. The immune
responses to schistosome antigens in chronically infected mice
and in humans with intestinal and hepatointestinal diseases are
characterized by high IL-4 and IL-5 and low IFN-g production,
which indicates a predominant Th2-type immune response,
although some investigators have found a preferential Th1-type
immune response in patients with hepatosplenic disease (high
TNF-a levels and low IL-5 levels in peripheral blood mono-
nuclear cell [PBMC] supernatants) [19–23]. In acute schistoso-
miasis, a Th1-type response, recognized by production of IL-2
and IFN-g, occurs in the first 5 weeks after infection in mice,
before the adult worm releases eggs [24, 25].
In humans with acute schistosomiasis, higher IFN-g and
lower IL-5 levels are found in supernatants from PBMC than
those found in supernatants from PBMC of patients with chronic
disease [26]. Chronically infected patients from areas in which
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schistosomiasis is endemic do not present with the toxemic
symptoms of acute schistosomiasis. The acute syndrome affects
persons not previously exposed to the parasite antigens, which
suggests an important modulatory effect of the immune system
in controlling the toxemic disease [2, 3, 13, 26]. However, the
role of immune response in the pathogenesis of human acute
schistosomiasis remains unclear.
In this study, we evaluated the immune responses of 31
patients with acute schistosomiasis who were exposed to the
same water source of infection and for a similar time period.
We correlated these responses with the patients’ clinical
abnormalities. We also compared the immune responses of per-
sons with acute schistosomiasis with those of chronically
infected persons in an area in which schistosomiasis is endemic.
Subjects and Methods
Study subjects and clinical evaluation. Patients with acute
schistosomiasis (n ¼ 35) were recruited from Aracaju, the capital
of Sergipe State, Brazil, from March through May 1999. Active
case finding was done by 2 infectious disease physicians after the
detection of acute schistosomiasis in 7 members of a family exposed
to water in the same lake in Abaı´s, 55 km south of Aracaju. All
patients were exposed to the same lake water. Abaı´s is a tourism
area heavily visited during holidays by people from Sergipe, other
Brazilian states, and foreign countries. The study population had
high socioeconomic and nutritional status. Inclusion criteria were
history of recent water contact in the Abaı´s lake, symptoms indi-
cating acute infectious disease, and initial S. mansoni egg–negative
stool examination results that became positive during the follow-
up period. Exclusion criteria were any past diagnosis of or treatment
for schistosomiasis. On the basis of these criteria, 4 patients were
excluded from the study.
The remaining 31 patients had complete clinical examinations
that included clinical history and physical examination, followed
by laboratory evaluation that included Kato-Katz stool examination
(a quantitative method for detection of S. mansoni eggs in stool
samples), total and differential blood cell counts, analysis of liver
enzymes (alanine aminotransferase [ALT], aspartate aminotrans-
ferase [AST], g-glutamyltransferase [g-GT], and alkaline phospha-
tase [AP]), and analysis of urea, creatinine, and urine (biochemical
and cellular components). Echocardiography, chest radiography,
and spirometry tests were also performed. Patients were initially
evaluated at 33–60 days after water exposure and were followed
up once a week with clinical examination and stool examination,
until the parasitologic results became positive for schistosome eggs.
During this weekly follow-up, all clinical support was given to the
patients until their major symptoms improved. They were also fol-
lowed up at 5 and 12 months after study enrollment with clinical
and laboratory examinations. All patients with S. mansoni eggs in
stool were treated with oxamniquine (15–20 mg/kg of body
weight).
Twenty-one ethnically similar patients with chronic schistoso-
miasis, who are part of a cohort study in the endemic area of Caa-
tinga do Moura, Bahia, were selected for comparison of their
immune responses with those of the patients with acute disease.
The patients with chronic disease were selected on the basis of pres-
ence of hepatic fibrosis (degree I or II), determined by abdominal
ultrasonography according to the 1992 World Health Organization
criteria [27]. Selection criteria for the control patients included simi-
lar ages and egg counts by Kato-Katz stool examination. The control
patients were compared with those with acute schistosomiasis in all
immunologic evaluations except total IgE. For analysis of total
IgE, we included 45 serum samples obtained from patients with
chronic schistosomiasis who were tested for total IgE 6 months be-
fore the acute-stage serum was tested. The patients with chronic
schistosomiasis from the endemic area are treated every 3 years
with praziquantel (30–50 mg/kg/body weight) per guidelines of
the National Foundation of Health of Brazil.
Parasitologic methods. Parasitologic examinations were done
by the Kato-Katz method [28–31], in which 42 mg of stool sample
is examined and the results are multiplied by 24 to give the number
of eggs per gram of stool. Two stool samples were collected from
each subject at the first evaluation (33–60 days after water
exposure) and each week thereafter until S. mansoni eggs were
detected. The parasitologic examinations were usually positive
60–120 days after water exposure.
Antigens. The antigens used were soluble extracts of adult par-
asites (SWAP) and of parasite eggs (SEA) [32, 33].
Immunologic procedures. The immunologic evaluation was
performed while the stool examinations were still negative for
eggs. Blood samples were obtained from 13 patients 33–45 days
after water exposure and from 18 patients 45–60 days after expo-
sure. Eighteen patients still had symptoms when the blood samples
were collected. Serum samples were aliquoted and were stored at
220C for later evaluation of total and S. mansoni–specific IgE,
TNF-a, and immune complex levels. Specific IgE to SEA was
measured by ELISA, as described elsewhere [32, 34]. Forty-five
stored serum samples from chronically infected patients who had
intestinal or hepatointestinal forms of disease were used as controls
for total IgE measurement. For SEA- and SWAP-specific IgE, the
chronically infected patients were the same as those used as control
patients for the evaluation of cellular immune responses.
Serum TNF-a levels were measured by using a commercial kit
(R&D Systems) per the manufacturer’s instructions. The cutoff
was 3 pg/mL (meanþ 2 SD of the concentration obtained from a
control group, selected from Brazilian S. mansoni–unexposed
medical students and laboratory workers).
Circulating immune complex levels were determined with a C1q
binding assay kit by following the manufacturer’s instructions
(CIC-C1Q; Buhlmann Laboratories). We expressed results in
microgram equivalents per milliliter, based on a standard curve
made with aggregated IgG. The cutoff was 3.2 mg Eq/mL.
The lymphoproliferative test was performed only in the patients
with acute schistosomiasis, as described elsewhere [35]. In brief,
PBMC were fractioned from total heparinized fresh blood by den-
sity gradient centrifugation (Histopaque 1077; Sigma Diagnostics).
PBMC were collected from the interface and were washed 3 times
with 0.9% saline. For lymphocyte proliferation, PBMC were
adjusted to 106 mL in RPMI 1660 with glutamine and bicarbonate
and were supplemented with 10% human AB serum. In all, 2 £ 105
cells in 200-mL aliquots were incubated in 96-well flat-bottom
plates, either without stimulus or stimulated with antigens SEA and
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SWAP (10 mg/mL) and mitogen pokeweed (1:100), and were
cultured for 5 days at 37C in a 5% CO2 humid incubator. In the
last 6 h, 1 mCi of [3H]thymidine was added to each well. Lympho-
cyte blastogenic data are shown as stimulation index (SI) = counts
per minute of the stimulated culture divided by the counts per min-
ute of the unstimulated culture.
The cytokine assay was performed as described elsewhere [32].
PBMC were adjusted to 3 £ 106 cells/mL in RPMI, and 1 mL was
cultured in each well of 24-well plates, either without any stimulus
or stimulated with SEA, SWAP, and mitogen phytohemagglutinin
(10 mg/mL of each). Cultures were incubated for 24 h (IL-1 and
IL-6) or for 72 h (IFN-g, IL-5, IL-10, and TNF-a) at 37C in a 5%
CO2 incubator. The supernatants from these cultures were used to
measure the cytokine levels by sandwich ELISA, using commercial
kits (IFN-g and TNF-a, Genzyme Diagnostics; IL-5, Pharmingen;
IL-1, -6, and -10, R&D Systems).
Statistical methods. IgE and cytokine levels of patients with
acute schistosomiasis were compared with those of the patients
with chronic infection, using the Mann-Whitney U test. Analyses
between 2 continuous variables were made with the Spearman cor-
relation test (InStat software). Associations between categorical
clinical data with the immunologic parameters were analyzed by
stratified statistical analysis (Fisher’s exact test; EpiInfo software).
Results were considered significant if, at a , 5%, P , :05. All
data are shown as mean ^ SD unless noted.
Results
Characteristics and infection status of study subjects. We
studied 31 patients with acute schistosomiasis: 11 male and 20
female patients. No significant differences were observed
between patients with acute and chronic disease in age
(21 ^ 10:5 and 19:3 ^ 9:2 years, respectively) or infection
levels (172 ^ 32:9 and 185 ^ 74:5 eggs/g of stool, respectively;
P ¼ :42 and P ¼ :09, respectively, Mann-Whitney U test.
Clinical manifestations of acute schistosomiasis. Clinical
data are shown in figure 1. All but 1 of the 31 patients exhibited
serious clinical symptoms. The first symptoms appeared 21–28
days after water exposure. Malaise and fever, present in 90% of
the patients, were the first complaints in order of occurrence,
followed by weight loss in 26 (83.9%), chills in 25 (80.6%),
headache in 27 (87.1%), myalgia in 23 (74.2%), and facial and
lower limb edema in 15 (48.4%). Diffuse abdominal pain
occurred in 29 patients (93.5%), diarrhea in 25 (80.6%), and
both symptoms in 23 patients (74.2%). Hepatosplenomegaly
was observed in 11 patients (35.5%), and hepatic enzyme levels
were high in 12 patients (38%). All hepatic enzyme levels
(AST, ALT, AP, and g-GT) were elevated in 3 patients, 3 had
elevated levels of AP and g-GT, 3 had only elevated AP levels,
and 3 had only elevated g-GT levels.
Respiratory problems were also evident as cough in 25
patients (80.6%), dyspnea in 16 (51.6%), chest pain in 12
(38.7%), and restrictive respiratory insufficiency in 9 (29%).
Interstitial infiltrates were observed on chest radiographic films
in 7 patients (23%). Echocardiography showed pericarditis in 6
patients (19%), and the chest radiographic films of these patients
showed interstitial infiltrates. Four patients had abnormal echo-
cardiography, chest radiography, and pulmonary function test
results. Eosinophil count was high in 30 patients (540–7380
eosinophils/mL); this was the abnormality most frequently
found by clinical examination. Leukocytosis was observed in 8
subjects (25.8%). One patient was admitted because of respira-
tory insufficiency, intense abdominal pain, ascites, and diarrhea
with dehydration. He was treated with prednisone (1 mg/kg of
body weight) for 4 days and with a single dose of oxamniquine
Figure 1. Clinical and laboratory data for 31 patients with acute schistosomiasis. Bars show frequency (%) of symptoms, signs, and abnormal
laboratory findings. *One patient did not undergo a blood cell count, but all patients (100%) had eosinophilia.
de Jesus et al.100 JID 2002;185 (1 January)
 at Escola Paulista M
edicina on O
ctober 15, 2015
http://jid.oxfordjournals.org/
D
ow
nloaded from
 
(20 mg/kg of body weight). The remaining patients were treated
as outpatients but needed intense medical assistance for 3 weeks:
1 patient received corticosteroids for 5 days because of respira-
tory insufficiency. Work absenteeism was 100% for as long as 2
weeks. The 5-month follow-up showed a persistent eosinophilia
in 29 patients (93.5%) and malaise in 11 (35.5%). Three patients
(9.7%) had abnormal spirometry and 4 (12.9%) had pericarditis.
No abnormalities were observed at the 12-month follow-up.
Immunologic findings of acute schistosomiasis. There was
no significant difference in total IgE level between patients
with acute and chronic schistosomiasis (724:8 ^ 1038:31 vs.
978:8 ^ 1325:2 IU/mL; figure 2A). SEA-specific IgE in patients
with acute disease had an OD of 0–4.27 at 450 nm (0:59 ^
1:06); in patients with chronic disease, OD was 0–2.55 (1:16 ^
0:99; P ¼ :07, Mann-Whitney U test; figure 2B). The OD at
450 nm for IgE specific to SWAP in patients with acute disease
was 0–0.128 (0:06 ^ 0:038) and did not differ significantly from
that in patients with chronic disease (0–0.224; 0:06 ^ 0:07);
P ¼ :16, Mann-Whitney U test (figure 2C). No correlation was
observed between eosinophil counts in peripheral blood and total
or SEA- or SWAP-specific IgE levels in patients with acute dis-
ease (P . :1, Spearman correlation test).
The most striking finding was that PBMC from most patients
with acute disease spontaneously released high levels of the
inflammatory triad TNF-a (1349:3 ^ 767:6 pg/mL), IL-1
(2683:2 ^ 1270:1 pg/mL), and IL-6 (381:8 ^ 52:3 pg/mL;
figure 3). In addition, detectable levels of IFN-g (93:6 ^
115:66 pg/mL) were present in the supernatants of unstimulated
PBMC from these patients (data not shown). In comparison,
nonstimulated PBMC from chronically infected patients pro-
duced little TNF-a or IFN-g spontaneously (24:7 ^ 54:87 and
2:1 ^ 6:92 pg/mL, respectively; P , :0001, Mann-Whitney U
test; data not shown). Stimulation of PBMC of patients with
acute disease with either SEA or SWAP did not result in in-
creased production of TNF-a, IL-1, or IL-6, but higher levels of
IFN-g were detected in SEA-stimulated PBMC (see figure 4).
TNF-a levels were also elevated in serum samples of 26
(87%) of 30 patients with acute disease who were tested (range,
0–85; 13:4 ^ 20:5 pg/mL). These levels were higher than those
observed in healthy control subjects (1:7 ^ 0:60 pg/mL;
P ¼ :0002) and in patients with chronic disease (6:9 ^ 3:9 pg/
mL), although the differences were not statistically significant
(P ¼ :82; figure 5). High levels of serum TNF-awere associated
with abdominal pain (P ¼ :02, Fisher’s exact test). There were
no significant differences between the lymphoproliferative re-
sponses of PBMC stimulated with SEA (SI, 3:01 ^ 3:71) and
SWAP (2:4 ^ 2:74; P ¼ :81, Mann-Whitney U test) in patients
with acute schistosomiasis (data not shown).
Figure 4 shows the cytokine profile in SEA-stimulated PBMC
supernatants. High levels of TNF-a (1016 ^ 742:04 pg/mL) and
IFN-g (330:9 ^ 502:7 pg/mL) production were detected in 30
(96.8%) and 22 (71%) of the patients with acute schistosomiasis,
respectively (figure 4A). These responses were significantly
higher than those of patients with chronic disease (TNF-a,
55 ^ 100:7 pg/mL; IFN-g, 98:5 ^ 363:13 pg/mL; P , :0006
for both, Mann-Whitney U test; figure 4B). The levels of IL-5
(154:5 ^ 277:6 pg/mL) and IL-10 (75:6 ^ 95:1 pg/mL) pro-
Figure 2. Total IgE (A), soluble egg antigen (SEA)–specific IgE
(B), and soluble (adult) worm antigen (SWAP)–specific IgE (C) from
patients with acute and chronic schistosomiasis. Bars show mean
values (OD450 nm). Differences between patients with acute and chronic
disease were not statistically significant (*P ¼ :07 and **P ¼ :16,
Mann-Whitney U test).
Figure 3. Levels of proinflammatory cytokines (interleukin [IL]–1,
IL-6, and tumor necrosis factor [TNF]–a) in unstimulated peripheral
blood mononuclear cell supernatants from patients with acute schisto-
somiasis. Bars show mean values. Levels of these cytokines (mean ^
SD pg=mL) in subjects with chronic schistosomiasis (n ¼ 10) were as
follows: IL-1, 13.5 ^ 36.59; IL-6, 66 ^ 147.4; TNF-a, 24.7 ^ 54.87.
Differences in the levels of each cytokine between patients with acute
and chronic disease were significant (P , :001 for each, Mann-Whit-
ney U test).
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duced by SEA-stimulated PBMC from patients with acute
disease were similar to those of patients with chronic disease
(IL-5, 87:7 ^ 231:4 pg/mL; IL-10, 90:5 ^ 66:6 pg/mL; P .
:10 for both, Mann-Whitney U test). In patients with acute dis-
ease, a direct correlation was observed between IL-10 levels in
SEA-stimulated PBMC and duration of infection (rs ¼ :44,
P ¼ :02, Spearman correlation test). In addition, low levels of
IL-5 in SEA-stimulated PBMC were associated with weight
loss (P ¼ :04, Fisher’s exact test). Low levels of IL-5 in PBMC
supernatants and high serum levels of TNF-a were associated
with abdominal pain (P , :002, Fisher’s exact test). The levels
of IL-5 produced in response to SWAP were significantly higher
for patients with chronic than for patients with acute schistoso-
miasis (987:4 ^ 2229:5 vs. 70:8 ^ 158:5 pg/mL; P ¼ :01,
Mann-Whitney U test; figure 6).
Immune complexes were detected in 17 (55%) of the patients
with acute schistosomiasis (7:8 ^ 7:6 mg Eq/mL) but in none of
12 patients with chronic schistosomiasis (0:8 ^ 0:6 mg Eq/mL)
or in 5 healthy subjects (1:7 ^ 1:6 mg Eq/mL; figure 7). An
association was observed between high levels of serum immune
complexes and cough, dyspnea, and abnormal chest radiograph-
ic findings (P ¼ :05 for each, Fisher’s exact test). Although no
significant association was found between pericarditis and de-
tection of immune complexes in serum (P ¼ :09), 5 of the 6 pa-
tients who had pericarditis had high levels of immune complexes
(range, 7.1–24.9 mg Eq/mL; 15 ^ 8:1 mg Eq/mL).
In 10 patients who were reevaluated 5 months after treatment,
serum TNF-a levels had decreased to the levels of control sub-
jects (before treatment, 7:2 ^ 4:9 pg/mL; after treatment, 1:7 ^
1:00 pg/mL; P ¼ :0021, Mann-Whitney U test). Spontaneous
production of proinflammatory cytokines in PBMC supernatants
was still seen 5 months after treatment but at lower levels than
before treatment (table 1).
Discussion
Acute schistosomiasis is a severe disease, and the mechanism
involved in its clinical manifestations is not completely under-
stood. In the present study, we clinically and immunologically
evaluated 31 patients exposed to the same body of contaminated
water. They were evaluated during the prepatent period, 33–60
days after exposure. The patients had symptoms that included
malaise, headache, myalgia, edema, and abdominal pain as well
as major organ involvement, such as liver and spleen enlarge-
ment, elevated liver enzymes, pericarditis, and restrictive respi-
ratory insufficiency.
Because eosinophilia is an important feature of acute schisto-
somiasis, some of the clinical findings (e.g., respiratory distress)
were attributed earlier to an immediate hypersensitivity mecha-
nism [3, 12, 13]. However, the patients with acute schistoso-
miasis in this study presented with respiratory insufficiency, but
with a restrictive rather than an obstructive pattern, suggesting
an interstitial pulmonary involvement. In addition, total and
Figure 4. Mean ^ SD cytokine levels (tumor necrosis factor
[TNF]–a, interferon [IFN]–g, and interleukin [IL]–5 and –10) in sol-
uble egg antigen–stimulated peripheral blood mononuclear cell super-
natants from patients with acute (A) and chronic (B) schistosomi-
asis. Percentages indicate patients with positive response levels
(>30 pg/mL).
Figure 5. Serum tumor necrosis factor (TNF)–a levels in patients
with acute vs. chronic schistosomiasis and healthy control subjects.
Bars show mean values. Cutoff is 3 pg/mL (mean + 2 SD of levels of
control subjects). *P ¼ :0002, Mann-Whitney U test.
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parasite-specific IgE levels were not associated with respiratory
symptoms. Similar IgE levels were found in persons with both
acute and chronic schistosomiasis, but respiratory distress is not
a feature of the chronic disease. Because immune complexes
were associated with cough, dyspnea, abnormal chest radio-
graphic findings, and pericarditis, it is likely that respiratory dis-
tress and pericarditis in acute schistosomiasis could be mediated
by immune complex deposition in these tissues. In fact, pulmo-
nary vasculitis and pericarditis are features of systemic lupus
erythematosus, an immune complex–mediated disease [36].
Constitutional symptoms were present in most patients with
acute schistosomiasis. Thus, mechanisms other than the immune
complex might be implicated in these symptoms. The high pro-
duction of the proinflammatory cytokines IL-1, IL-6, and
TNF-a found in cultures of unstimulated PBMC from patients
with acute schistosomiasis and the detection of TNF-a in the
serum of 87% of these patients could explain all constitutional
symptoms and some of the organ involvement. Active secretion
of proinflammatory cytokines by PBMC ex vivo might indicate
that those persons were in the process of mounting an aggressive
immune response when samples were obtained. Alternatively,
the parasite antigens could drive a direct activation of the innate
immunity. Production of these proinflammatory mediators oc-
curred in the absence of appreciable levels of the anti-inflamma-
tory cytokine IL-10. In fact, in IL-4 and IL-10 knockout mice
infected with S. mansoni, the high mortality rate was related to
inflammatory mediators [19, 37–39]. The ability of proinflam-
matory cytokines to mediate tissue damage has been described
in bacterial toxemic shock, meningitis, cerebral malaria, leish-
maniasis, and hanseniasis [40–45].
People residing where schistosomiasis is endemic usually do
not present with acute disease, suggesting that the adaptive
immune response protects them from developing the acute tox-
emic condition [2, 3, 13, 26, 46–48]. Patients with chronic intesti-
nal and hepatointestinal schistosomiasis present with a Th2-type
immune response, with low or no IFN-g production in response
to parasite antigens [20–22], although Mwatha et al. [23]
reported a higher production of IFN-g and TNF-a in hepato-
splenic schistosomiasis. Montenegro et al. [27] found a dominant
Th1 response in patients with acute schistosomiasis; however,
the patients had been infected for 120 days, had positive parasi-
tologic results, and had very high IL-10 levels in PBMC
supernatants.
The present study clearly shows higher levels of IFN-g pro-
duction in patients with acute schistosomiasis than in persons
with chronic schistosomiasis. However, fewer patients with
acute disease produced IL-10 in response to SEA, when com-
pared with the patients with chronic disease. We also found a
positive correlation between IL-10 levels in SEA-stimulated
PBMC and time after water exposure. Because Montenegro
et al. [27] detected higher levels of this cytokine in later stages
of disease (120 days), we hypothesize that, after egg secretion,
IL-10 might be one of the cytokines involved in down-regulating
the Th1 response, which dominates the early acute phase of dis-
ease. In the present study, low IL-5 levels were detected in
patients with acute schistosomiasis, but persons with chronic
disease exhibited a high IL-5 response to SWAP. In addition,
low IL-5 levels in SEA-stimulated PBMC from the patients
with acute disease were associated with weight loss. These data
suggest that the Th2-type response seen in patients with chronic
schistosomiasis may serve as an anti-inflammatory modulator
of the toxemic symptoms of acute schistosomiasis. In fact, the
role of the Th2-type response in preventing tissue damage and
preventing the development of a severe inflammatory disease
during acute schistosomiasis has been documented in knockout
mice for IL-4 and IL-10 genes [37–39].
Although morbidity due to chronic schistosomiasis has
decreased because of the availability of effective drugs, such as
oxamniquine and praziquantel, acute schistosomiasis continues
to be a serious health problem because it is potentially fatal,
Figure 6. Interferon (IFN)–g (A) and interleukin (IL)–5 (B) levels
(mean ^ SD) in soluble adult worm antigen–stimulated peripheral
blood mononuclear cell supernatants of patients with acute (n ¼ 31)
and chronic (n ¼ 21) schistosomiasis. P values represent differences
between cytokine levels in patients with acute and chronic disease
(Mann-Whitney U test).
Figure 7. Serum immune complex levels in patients with acute
schistosomiasis, compared with patients with chronic schistosomiasis
and healthy control subjects. Bars show mean values. Cutoff represents
normal level of commercial kit used (3.2 mg Eq/mL). *P , :0001,
Mann-Whitney U test.
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especially schistosomiasis due to S. japonicum infection. Dis-
eases usually result from parasite products in tissue and from
the chemical compounds produced by innate and adaptive
immune responses of the host. Adaptive mechanisms of the
host interact with infectious organisms to control their growth
and neutralize their products and usually mount a balanced
immune response and do not cause excessive tissue damage.
The results of our study suggest that the severe toxemic syn-
drome and major organ involvement observed in acute schisto-
somiasis are mediated by proinflammatory cytokines and
immune complexes and that an absence of a Th2-type response,
which could exert an anti-inflammatory response, contributes to
maintaining the toxemic symptoms. Our data shed light on the
immunopathogenesis of acute disease due to S. mansoni infec-
tion. Similar mechanisms might operate in acute S. japonicum,
an even more severe condition, and should be studied. Cortico-
steroids are usually needed for treatment of patients with severe
cases of acute schistosomiasis [10, 11, 13], but this drug pro-
duces a generalized immune suppression. Understanding the
pathogenesis of this severe disease will enable development of
other therapeutic measures based on immune modulators.
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